Table 3.
Lipid-profile variables at the beginning and end of the supplementation and placebo periods in population with dyslipidemia.
| SAx (n = 67) |
Placebo (n = 67) |
|||
|---|---|---|---|---|
| TC | (mg/dL) (n = 49) |
Start End Change |
237.6 ± 26.0 234.9 ± 25.1 −2.776 ± 18.8 |
238.4 ± 20.0 233.0 ± 22.8 −5.388 ± 18.8 |
| LDL-C | (mg/dL) | Start | 179.1 ± 16.2 | 171.6 ± 9.1 |
| (n = 16) | End | 162.9 ± 27.1 ** | 163.6 ± 16.9 | |
| Change | −16.20 ± 18.5 | −8.063 ± 15.1 | ||
| HDL-C | (mg/dL) | Start | 44.25 ± 4.0 | 41.50 ± 5.2 |
| (n = 8) | End | 48.00 ± 7.3 * | 43.75 ± 8.3 | |
| Change | 3.750 ± 4.0 | 2.250 ± 5.4 | ||
| TG | (mg/dL) | Start | 200.7 ± 51.4 | 186.0 ± 51.5 |
| (n = 4) | End | 155.3 ± 42.4 * | 170.5 ± 50.3 | |
| Change | −45.33 ± 10.5 | −15.50 ± 73.1 |
Data expressed as means ± standard deviations (SDs); SAx: oral supplementation with hydroxytyrosol (HT) and punicalagin (PC); TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; and TG: triglycerides. In the present clinical trial, significant differences were observed between the beginning and end of the SAx period (* p < 0.05, ** p < 0.01). There were no significant differences in the placebo period or in the changes in the different intervention periods.